Well, REH, I am impressed with your familiarity with all these MXR related issues.
Clearly you have the same level of interest with Medix as I have with Hypertension Diagnostics (HDII). My interest with HDII, however, remains at a very optimistic level. I feel substantial stock price appreciation is on the horizon for the numerous reasons I've outlined on the SI HDII thread. If I were to come close to approaching your attitude towards MXR with respect to HDII, I would sell the HDII tomorrow and not waste my time posting on the thread.
And so the obvious question arises: if you have such a low opinion of every aspect of Medix, deserved or not, why the hell are you invested in it? If you can only view every move by Medix in the worse possible light, why bother with it? Take your loss like and man and put your money to work where you perceive you can get some REAL returns. Every company deserves some degree of sh_t shoved in their face but if all you see is brown behind the officer's eyelid's, then why bother with this cr_p? If all you can list is 'concerns', with no upside whatsoever, what in god’s name is the logic behind your investment here (are you holding out hoping to recapture some capital following a poorly timed investment during the internet bubble?)? I mean it: just move on and get this lousy company out of your system!
Certainly there's a role for criticism...but there's a role for balance as well. Prudent investors see both sides of a company's claims. If all you see is the positive, you've got the rose-colored-glasses thing. If all you see is doom and gloom, the stock ought not be your sweat equity.
And gee, I wonder if MXR's stock collapse, which obviously underlies your entire picture, is at all related to the virtual annihilation of the BtB sector. Many of MXR's brethren are down worse than MXR...and many have vanished into the contract-absent abyss.
In any event, you say, ' Pfeil leaving must have been a surprise or there would have been a replacement named – at least a temporary one.' and I say (AGAIN), no, there mustn't be if the position was eliminated as part of a consolidation program (where the CTO responsibilities are incorporated in to the parent company). But that would involve giving the company the benefit of the doubt which is a concept the fails the modus operanditest around here.
MXR (a.k.a. NURS) is a tiny fraction of my portfolio and always has been. But I certainly wouldn't even consider maintaining this trivial holding if my outlook for the company came within light years of yours.
Cheers!
Scott. |
